These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8820957)

  • 1. Role of c-Fes in normal and neoplastic hematopoiesis.
    Yates KE; Gasson JC
    Stem Cells; 1996 Jan; 14(1):117-23. PubMed ID: 8820957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
    Rogers JA; Cheng HY; Smithgall TE
    Cell Growth Differ; 2000 Nov; 11(11):581-92. PubMed ID: 11095247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713).
    Hjermstad SJ; Peters KL; Briggs SD; Glazer RI; Smithgall TE
    Oncogene; 1993 Aug; 8(8):2283-92. PubMed ID: 7687763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
    Lionberger JM; Smithgall TE
    Cancer Res; 2000 Feb; 60(4):1097-103. PubMed ID: 10706130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSH2: a novel SH2 domain-containing adapter protein involved in tyrosine kinase signaling in hematopoietic cells.
    Oda T; Muramatsu MA; Isogai T; Masuho Y; Asano S; Yamashita T
    Biochem Biophys Res Commun; 2001 Nov; 288(5):1078-86. PubMed ID: 11700021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of c-Fes tyrosine kinase activity by coiled-coil and SH2 domains: analysis with Saccharomyces cerevisiae.
    Takashima Y; Delfino FJ; Engen JR; Superti-Furga G; Smithgall TE
    Biochemistry; 2003 Apr; 42(12):3567-74. PubMed ID: 12653561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Fes kinase activity in myeloid cell growth and differentiation.
    Yates KE; Crooks GM; Gasson JC
    Stem Cells; 1996 Nov; 14(6):714-24. PubMed ID: 8948028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human c-FES is a nuclear tyrosine kinase.
    Yates KE; Lynch MR; Wong SG; Slamon DJ; Gasson JC
    Oncogene; 1995 Mar; 10(6):1239-42. PubMed ID: 7700650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP; Sefton BM
    Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncation of c-fes via gene targeting results in embryonic lethality and hyperproliferation of hematopoietic cells.
    Hackenmiller R; Simon MC
    Dev Biol; 2002 May; 245(2):255-69. PubMed ID: 11977979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Fps/Fes tyrosine kinase regulates erythroid differentiation and survival.
    Sangrar W; Gao Y; Bates B; Zirngibl R; Greer PA
    Exp Hematol; 2004 Oct; 32(10):935-45. PubMed ID: 15504549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and structural analysis of murine c-fes cDNA clones.
    Wilks AF; Kurban RR
    Oncogene; 1988 Sep; 3(3):289-94. PubMed ID: 3060793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
    Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
    Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant transformation of a human fibroblast cell strain by transfection of a v-fes oncogene but not by transfection of a gag-human c-fes construct.
    Lin C; Wang Q; Maher VM; McCormick JJ
    Cell Growth Differ; 1994 Dec; 5(12):1381-7. PubMed ID: 7696187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signalling by the p60c-src family of protein-tyrosine kinases.
    Kefalas P; Brown TR; Brickell PM
    Int J Biochem Cell Biol; 1995 Jun; 27(6):551-63. PubMed ID: 7545532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification and preliminary crystallographic studies on the catalytic region of the nonreceptor tyrosine kinase Fes.
    Gnemmi I; Scotti C; Cappelletti D; Canonico PL; Condorelli F; Rosano C
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Jan; 63(Pt 1):18-20. PubMed ID: 17183165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p60c-src family of protein-tyrosine kinases: structure, regulation, and function.
    Brickell PM
    Crit Rev Oncog; 1992; 3(4):401-46. PubMed ID: 1384720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src protein-tyrosine kinase structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Nov; 324(4):1155-64. PubMed ID: 15504335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
    Liebermann DA; Hoffman B
    Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.